Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats

被引:25
作者
Rakusan, Dan [1 ,2 ]
Kujal, Petr [2 ,3 ]
Kramer, Herbert J. [4 ]
Huskova, Zuzana [2 ,6 ]
Vanourkova, Zdenka [2 ,6 ]
Vernerova, Zdenka [2 ,3 ]
Mrazova, Iveta [2 ,6 ]
Thumova, Monika [2 ,6 ]
Cervenka, Ludek [2 ,5 ,6 ]
Vaneckova, Ivana [2 ,6 ]
机构
[1] Charles Univ Prague, Dept Med, Fac Med 1, Nephrol Sect, Prague, Czech Republic
[2] Charles Univ Prague, Inst Clin & Expt Med, Ctr Med Expt, Prague, Czech Republic
[3] Charles Univ Prague, Fac Med 3, Dept Pathol, Prague, Czech Republic
[4] Univ Bonn, Med Policlin, Nephrol Sect, D-5300 Bonn, Germany
[5] Charles Univ Prague, Fac Med 2, Dept Physiol, Prague, Czech Republic
[6] Charles Univ Prague, Cardiovasc Res Ctr, Prague, Czech Republic
关键词
losartan; hypertension; direct renin inhibition; glomerular size; morphometry; washout period; blood pressure; FILTRATION BARRIER INJURY; DIRECT RENIN INHIBITION; BLOOD-PRESSURE; RECEPTOR BLOCKADE; (PRO)RENIN RECEPTOR; HYPERTENSIVE-RATS; PODOCYTE INJURY; AT(1)R BLOCKADE; ANGIOTENSIN-II; ORGAN DAMAGE;
D O I
10.1152/ajprenal.00259.2010
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Rakusan D, Kujal P, Kramer HJ, Huskova Z,Vanourkova Z,Vernerova Z, Mrazova I, Thumova M, Cervenka L, Vaneckova I. Persistent antihypertensive effect of aliskiren is accompanied by reduced proteinuria and normalization of glomerular area in Ren-2 transgenic rats. Am J Physiol Renal Physiol 299: F758-F766, 2010. First published July 28, 2010; doi:10.1152/ajprenal.00259.2010.-The effects of the human renin inhibitor aliskiren on blood pressure (BP), end-organ damage, proteinuria, and tissue and plasma angiotensin (ANG) II levels in young and adult heterozygous Ren-2 transgenic rats (TGR) were evaluated and compared with the effect of the ANG type 1 (AT(1)) receptor blocker losartan during treatment and after 12 days after the withdrawal of drug treatments. BP was monitored by telemetry from the age of 32 days on (young rats) and at 100 days (adult rats). Aliskiren (10 mg.kg(-1).day(-1) in osmotic minipumps) or losartan (5 mg.kg(-1).day(-1) in drinking water) treatment was applied for 28 days in young rats and for 70 days in adult rats. In young untreated TGR, severe hypertension rapidly evolved. Adult untreated TGR exhibited stable established hypertension. Both aliskiren and losartan fully prevented the development of hypertension and cardiac hypertrophy in young TGR and normalized BP and cardiac hypertrophy in adult TGR. After cessation of aliskiren treatment in both young and adult TGR BP and cardiac hypertrophy were persistently reduced, while after losartan withdrawal BP and cardiac hypertrophy rapidly increased. In adult aliskiren-treated rats proteinuria was significantly reduced compared with losartan (the effect persisting after withdrawal of treatment), and this decrease strongly correlated with normalization of glomerular size in these animals. In conclusion, aliskiren and losartan had similar antihypertensive effects during chronic treatment, but the antihypertensive and organoprotective effects of aliskiren were persistent even after the 12-day washout period. The durable effect on proteinuria can possibly be attributed to the normalization of glomerular morphology.
引用
收藏
页码:F758 / F766
页数:9
相关论文
共 38 条
[1]   Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells [J].
Batenburg, Wendy W. ;
de Bruin, Rene J. A. ;
van Gool, Jeanette M. G. ;
Mueller, Dominik N. ;
Bader, Michael ;
Nguyen, Genevieve ;
Danser, A. H. Jan .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (06) :1151-1157
[2]   High human renin hypertension in transgenic rats [J].
Bohlender, J ;
Fukamizu, A ;
Lippoldt, A ;
Nomura, T ;
Dietz, R ;
Menard, J ;
Murakami, K ;
Luft, FC ;
Ganten, D .
HYPERTENSION, 1997, 29 (01) :428-434
[3]   Differences in pharmacology and their translation into differences in clinical efficacy - a comparison of the renin angiotensin blocking agents irbesartan and losartan [J].
Bramlage, Peter ;
Schindler, Christoph .
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (04) :521-535
[4]   Aliskiren: Renin inhibitor for hypertension management [J].
Cheng, Judy W. M. .
CLINICAL THERAPEUTICS, 2008, 30 (01) :31-47
[5]   Low-dose renin inhibitor and low-dose AT1-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes [J].
Dechend, Ralf ;
Shagdarsuren, Erdenechimeg ;
Gratze, Petra ;
Fiebeler, Anette ;
Pilz, Bernhard ;
Meiners, Silke ;
Derer, Wolfgang ;
Feldman, David L. ;
Webb, Randy ;
Muller, Dominik N. .
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, 2007, 8 (02) :81-84
[6]   Effects of Aliskiren on Blood Pressure, Albuminuria, and (Pro)Renin Receptor Expression in Diabetic TG(mRen-2)27 Rats [J].
Feldman, David L. ;
Jin, Liang ;
Xuan, Hong ;
Contrepas, Aurelie ;
Zhou, Yinong ;
Webb, Randy L. ;
Mueller, Dominik N. ;
Feldt, Sandra ;
Cumin, Frederick ;
Maniara, Wieslawa ;
Persohn, Elke ;
Schuetz, Helmut ;
Danser, A. H. Jan ;
Nguyen, Genevieve .
HYPERTENSION, 2008, 52 (01) :130-136
[7]   New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease [J].
Feldman, David L. .
HYPERTENSION RESEARCH, 2010, 33 (04) :279-287
[8]  
FELDMAN DL, 2006, J CLIN HYPERTENS, V8, P80
[9]   Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage [J].
Funke-Kaiser, Heiko ;
Zollmann, Frank S. ;
Schefe, Jan H. ;
Unger, Thomas .
HYPERTENSION RESEARCH, 2010, 33 (02) :98-104
[10]   Optimal nephroprotection: Use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials [J].
Halimi, J. -M. ;
Asmar, R. ;
Ribstein, J. .
DIABETES & METABOLISM, 2009, 35 (06) :425-430